Table 1 Participant characteristics
Variable | Healthy Control (Group I) | CVD without Enhancement (Group II) | CVD with Enhancement (Groups III, IV) | p-value |
|---|---|---|---|---|
(n = 10) | (n = 24) | (n = 23) | ||
Demographics | ||||
Age (yrs) | 51.74 ± 4.7 | 47.7 ± 16.5 | 51.39 ± 15.4 | .406 |
BMI (kg/m2) | 23.32 ± 1.5 | 29.3 ± 6.7 | 27.4 ± 3.6 | .007 |
Female | 4 (50.0) | 8 (33.3) | 4 (17.4) | .315 |
White | 9 (90.0) | 20 (83.3) | 18 (78.3) | .815 |
African American | 0 | 3 (12.5) | 3 (13.0) | 1.00 |
Hispanic or Other Race | 1 (10.0) | 1 (4.2) | 2 (8.7) | .051 |
CMR Indication | ||||
Cardiomyopathy | 7 (29.2) | 10 (43.5) | .371 | |
Hypertrophic Cardiomyopathy | 2 (8.3) | 1 (4.3) | 1.000 | |
Pericarditis, Myocarditis | 2 (8.3) | 2 (8.7) | 1.000 | |
Sarcoidosis | 2 (8.3) | 2 (8.7) | 1.000 | |
Syncope | 4 (16.7) | 0 | .109 | |
Viability | 3 (12.5) | 5 (21.1) | .461 | |
Other | 4 (16.7) | 3 (17.4) | 1.000 | |
Diagnosis | ||||
Ischemic Cardiomyopathy | 4 (16.7) | 10 (43.5) | .060 | |
Non-Ischemic Cardiomyopathy | 10 (41.7) | 7 (30.4) | .547 | |
Hypertrophic Cardiomyopathy | 0 | 2 (8.7) | .234 | |
No Evidence of Cardiomyopathy | 8 (33.3) | 0 | .416 | |
Other | 2 (8.3) | 4 (17.4) | .416 | |
Ejection Fraction (%) | 50.13 ± 14.4 | 42.57 ± 14.6 | .081 | |
End Diastolic Volume (mL) | 190.6 ± 76.0 | 217.65 ± 81.1 | .244 |